The Life Raft Group is committed to enhancing the survival and quality of life for people living with Gastrointestinal Stromal Tumor (GIST), and other rare diseases, through patient-powered research, education and empowerment, and global advocacy efforts.
Other Programs Supported by The Life Raft Group:
PATIENT
Leverage patient perspective to drive innovative solutions in cancer research.
POWERED
Educate and empower patients to take a larger role in their care.
SCIENCE
Accelerate research outcomes through collaborative efforts.
FOR LIFE
Increase access to effective treatments worldwide.
Real World Evidence In Action
Traditional models for cancer research have resulted in many breakthrough treatments for patients, but it is not enough. The LRG’s approach to GIST research through real world evidence, relies on timely, accurate data from the patient’s perspective, with patient survival as the primary objective.
RECENT LRG DATA
Did you know that GIST is actually a family of cancers? Learn more about the science of GIST.
Update your Patient Registry Info.
Join The Life Raft Group.
Current GIST Clinical Trials.
Search the GIST Specialist Database.
Dr. Monica Anderson
Diagnosed in 2012 with Adult GIST.
Bella Rocco
Diagnosed in 2009 with Pediatric
(SDH-deficient) GIST.
HELP US SAVE LIVES
The Life Raft Group is a community and it is up to all of us to make a difference. There are many ways to help. We always need patient tissue and data in our GIST patient registry. Volunteering your time or making a monetary donation also helps us drive research forward and save lives.
News
LRG Supports New Jersey Legislation to Limit Patient Cost Sharing
Although GIST is among the few rare diseases that has oral chemotherapy drug treatment options available to its patients, the cost [...]
GIST Collaborative Tissue Bank: A researcher’s perspective
The Life Raft Group GIST Collaborative Tissue Bank consists of a collection of tumor specimens from a large number of patients, [...]
Generic Imatinib Approved in the US for CML: What does it mean for GIST patients?
On February 1, 2016, the commercial launch of the generic version of imatinib mesylate (Gleevec), for CML (Chronic Myeloid Leukemia) was approved by the FDA after the Novartis patent expiration and will become available for the first time in the United States through Sun Pharmaceuticals.
How To S.T.O.P. Caregiver Burnout
According to a 2015 report by the National Alliance of Caregivers, approximately 43.5 million adults in the United States provided unpaid [...]
All We Need is Love: A collection of messages and images from the heart
Dear LRG Community, Thanks to our: Caregivers, the unsung heroes who care for and give to our patients every day Research [...]
GIST Cancer Journal Winter 2015 Issue
The Life Raft Group is pleased to announce the release of the eighth issue of The GIST Cancer Journal, the official [...]
GIST Patients: Top Ten Tips To Avoid The Flu
Fall and winter mark the beginning of the flu season which is a concern for GIST patients. Though the weather [...]
Liquid Biopsy Holds Promise for Precision Medicine
In a recent release from the Translational Genomics Research Institute (TGen), it was reported that researchers have discovered that by analyzing circulating [...]
Keep up with the latest news, events, and opportunities to help.
To contact The Life Raft Group, please call 973-837-9092
PARTNERS & AFFILIATIONS
